SOAT1 and atherosclerosis: While in the past, SOAT inhibition has been explored for the treatment of atherosclerosis [48], more recently, the SOAT1 inhibitor nevanimibe was tested in a phase I clinical trial as a treatment of adrenocortical carcinoma (ACC).